176
G. Yang and Y. Huang
214. Li Y, Duo Y, Bi J, Zeng X, Mei L, Bao S, He L, Shan A, Zhang Y, Yu X (2018) Targeted
delivery of anti-miR-155 by functionalized mesoporous silica nanoparticles for colorectal
cancer therapy. Int J Nanomedicine 13 (1178–2013 Electronic):1241–1256
215. Zhang F, Correia A, Makila E, Li W, Salonen J, Hirvonen JJ, Zhang H, Santos HA (2017)
Receptor-Mediated surface charge inversion platform based on porous silicon nanoparticles
for efficient cancer cell recognition and combination therapy. ACS Appl Mater Interfaces
9(11):10034–10046
216. Sakhtianchi R, Darvish B, Mirzaie Z, Dorkoosh F, Shanehsazzadeh S, Dinarvand R (2019)
Pegylated magnetic mesoporous silica nanoparticles decorated with AS1411 Aptamer as a
targeting delivery system for cytotoxic agents. Pharm Dev Technol 24(9):1063–1075
217. Alibolandi M, Mohammadi M, Taghdisi SM, Ramezani M, Abnous K (2017) Fabrication of
aptamer decorated dextran coated nano-graphene oxide for targeted drug delivery. Carbohydr
Polym 155 (1879–1344 Electronic):218–229
218. Malik MT, O’Toole MG, Casson LK, Thomas SD, Bardi GT, Reyes-Reyes EM, Ng CK,
Kang KA, Bates PJ (2015) AS1411-conjugated gold nanospheres and their potential for
breast cancer therapy. Oncotarget 6(26):22270–22281
219. Dam DH, Culver KS, Kandela I, Lee RC, Chandra K, Lee H, Mantis C, Ugolkov A, Mazar
AP, Odom TW (2015) Biodistribution and in vivo toxicity of aptamer-loaded gold nanostars.
Nanomed-Nanotechnol 11(3):671–679
220. Deng R, Shen N, Yang Y, Yu H, Xu S, Yang YW, Liu S, Meguellati K, Yan F (2018) Targeting
epigenetic pathway with gold nanoparticles for acute myeloid leukemia therapy. Biomaterials
167 (1878–5905 Electronic):80–90
221. Kabirian-Dehkordi S, Chalabi-Dchar M, Mertani HC, Le Guellec D, Verrier B, Diaz JJ,
Mehrgardi MA, Bouvet P (2019) AS1411-conjugated gold nanoparticles affect cell proliferation through a mechanism that seems independent of nucleolin. Nanomed-Nanotechnol
21:102060
222. Zhu YJ, Li WJ, Hong ZY, Tang AN, Kong DM (2017) Stable, polyvalent aptamer-conjugated
near-infrared fluorescent nanocomposite for high-performance cancer cell-targeted imaging
and therapy. J Mater Chem B 5(46):9229–9237
223. Guo C, Su F, Song Y, Hu B, Wang M, He L, Peng D, Zhang Z (2017) Aptamer-Templated
silver nanoclusters embedded in zirconium metal-organic framework for bifunctional electrochemical and SPR aptasensors toward carcinoembryonic antigen. ACS Appl Mater Interfaces
9(47):41188–41199
224. Xing H, Tang L, Yang X, Hwang K, Wang W, Yin Q, Wong NY, Dobrucki LW, Yasui N,
Katzenellenbogen JA, Helferich WG, Cheng J, Lu Y (2013) Selective delivery of an anticancer
drug with aptamer-functionalized liposomes to breast cancer cells in vitro and in vivo. J Mater
Chem B 1(39):5288–5297
225. Westra ER, Buckling A, Fineran PC (2014) CRISPR-Cas systems: beyond adaptive immunity.
Nat Rev Microbiol 12(5):317–326
226. Liao ZX, Chuang EY, Lin CC, Ho YC, Lin KJ, Cheng PY, Chen KJ, Wei HJ, Sung HW (2015)
An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for
tumor-specific chemotherapy that overcomes multidrug resistance. J Control Release 208
(1873–4995 Electronic):42–51
227. Yu S, Bi X, Yang L, Wu S, Yu Y, Jiang B, Zhang A, Lan K, Duan S (2019) Co-Delivery of paclitaxel and plk1-targeted sirna using aptamer-functionalized cationic liposome for synergistic
anti-breast cancer effects in vivo. J Biomed Nanotechnol 15(6):1135–1148
228. Riccardi C, Fabrega C, Grijalvo S, Vitiello G, D’Errico G, Eritja R, Montesarchio D (2018)
AS1411-decorated niosomes as effective nanocarriers for Ru(III)-based drugs in anticancer
strategies. J Mater Chem B 6(33):5368–5384
229. Xu L, He XY, Liu BY, Xu C, Ai SL, Zhuo RX, Cheng SX (2018) Aptamer-functionalized
albumin-based nanoparticles for targeted drug delivery. Colloids Surf B Biointerfaces 171
(1873–4367 Electronic):24–30
230. Qi J, Zhang Y, Gou Y, Lee P, Wang J, Chen S, Zhou Z, Wu X, Yang F, Liang H (2016)
Multidrug delivery systems based on human serum albumin for combination therapy with
three anticancer agents. Mol Pharm 13(9):3098–3105
G. Yang and Y. Huang
214. Li Y, Duo Y, Bi J, Zeng X, Mei L, Bao S, He L, Shan A, Zhang Y, Yu X (2018) Targeted
delivery of anti-miR-155 by functionalized mesoporous silica nanoparticles for colorectal
cancer therapy. Int J Nanomedicine 13 (1178–2013 Electronic):1241–1256
215. Zhang F, Correia A, Makila E, Li W, Salonen J, Hirvonen JJ, Zhang H, Santos HA (2017)
Receptor-Mediated surface charge inversion platform based on porous silicon nanoparticles
for efficient cancer cell recognition and combination therapy. ACS Appl Mater Interfaces
9(11):10034–10046
216. Sakhtianchi R, Darvish B, Mirzaie Z, Dorkoosh F, Shanehsazzadeh S, Dinarvand R (2019)
Pegylated magnetic mesoporous silica nanoparticles decorated with AS1411 Aptamer as a
targeting delivery system for cytotoxic agents. Pharm Dev Technol 24(9):1063–1075
217. Alibolandi M, Mohammadi M, Taghdisi SM, Ramezani M, Abnous K (2017) Fabrication of
aptamer decorated dextran coated nano-graphene oxide for targeted drug delivery. Carbohydr
Polym 155 (1879–1344 Electronic):218–229
218. Malik MT, O’Toole MG, Casson LK, Thomas SD, Bardi GT, Reyes-Reyes EM, Ng CK,
Kang KA, Bates PJ (2015) AS1411-conjugated gold nanospheres and their potential for
breast cancer therapy. Oncotarget 6(26):22270–22281
219. Dam DH, Culver KS, Kandela I, Lee RC, Chandra K, Lee H, Mantis C, Ugolkov A, Mazar
AP, Odom TW (2015) Biodistribution and in vivo toxicity of aptamer-loaded gold nanostars.
Nanomed-Nanotechnol 11(3):671–679
220. Deng R, Shen N, Yang Y, Yu H, Xu S, Yang YW, Liu S, Meguellati K, Yan F (2018) Targeting
epigenetic pathway with gold nanoparticles for acute myeloid leukemia therapy. Biomaterials
167 (1878–5905 Electronic):80–90
221. Kabirian-Dehkordi S, Chalabi-Dchar M, Mertani HC, Le Guellec D, Verrier B, Diaz JJ,
Mehrgardi MA, Bouvet P (2019) AS1411-conjugated gold nanoparticles affect cell proliferation through a mechanism that seems independent of nucleolin. Nanomed-Nanotechnol
21:102060
222. Zhu YJ, Li WJ, Hong ZY, Tang AN, Kong DM (2017) Stable, polyvalent aptamer-conjugated
near-infrared fluorescent nanocomposite for high-performance cancer cell-targeted imaging
and therapy. J Mater Chem B 5(46):9229–9237
223. Guo C, Su F, Song Y, Hu B, Wang M, He L, Peng D, Zhang Z (2017) Aptamer-Templated
silver nanoclusters embedded in zirconium metal-organic framework for bifunctional electrochemical and SPR aptasensors toward carcinoembryonic antigen. ACS Appl Mater Interfaces
9(47):41188–41199
224. Xing H, Tang L, Yang X, Hwang K, Wang W, Yin Q, Wong NY, Dobrucki LW, Yasui N,
Katzenellenbogen JA, Helferich WG, Cheng J, Lu Y (2013) Selective delivery of an anticancer
drug with aptamer-functionalized liposomes to breast cancer cells in vitro and in vivo. J Mater
Chem B 1(39):5288–5297
225. Westra ER, Buckling A, Fineran PC (2014) CRISPR-Cas systems: beyond adaptive immunity.
Nat Rev Microbiol 12(5):317–326
226. Liao ZX, Chuang EY, Lin CC, Ho YC, Lin KJ, Cheng PY, Chen KJ, Wei HJ, Sung HW (2015)
An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for
tumor-specific chemotherapy that overcomes multidrug resistance. J Control Release 208
(1873–4995 Electronic):42–51
227. Yu S, Bi X, Yang L, Wu S, Yu Y, Jiang B, Zhang A, Lan K, Duan S (2019) Co-Delivery of paclitaxel and plk1-targeted sirna using aptamer-functionalized cationic liposome for synergistic
anti-breast cancer effects in vivo. J Biomed Nanotechnol 15(6):1135–1148
228. Riccardi C, Fabrega C, Grijalvo S, Vitiello G, D’Errico G, Eritja R, Montesarchio D (2018)
AS1411-decorated niosomes as effective nanocarriers for Ru(III)-based drugs in anticancer
strategies. J Mater Chem B 6(33):5368–5384
229. Xu L, He XY, Liu BY, Xu C, Ai SL, Zhuo RX, Cheng SX (2018) Aptamer-functionalized
albumin-based nanoparticles for targeted drug delivery. Colloids Surf B Biointerfaces 171
(1873–4367 Electronic):24–30
230. Qi J, Zhang Y, Gou Y, Lee P, Wang J, Chen S, Zhou Z, Wu X, Yang F, Liang H (2016)
Multidrug delivery systems based on human serum albumin for combination therapy with
three anticancer agents. Mol Pharm 13(9):3098–3105